Kramer Robin, Chief Accounting Officer, has engaged exclusively in selling activity across two companies—Biogen Inc. (BIIB) and Armata Pharmaceuticals, Inc. (ARMP)—according to SEC Form 4 filings. Over 29 reported transactions, Robin has sold a total of $619,217.32 in BIIB shares, with no recorded purchases in either company. The sales were concentrated in Biogen, with multiple transactions in February 2024, February 2025, and February 2026, including a $213,854.34 sale on February 6, 2026, and a $59,040.10 sale on February 9, 2024. The filings also show several smaller dispositions, such as $34,922.30 on February 10, 2025, and $32,793.20 on February 7, 2025.
While Robin’s transactions in ARMP were marked as derivative awards (code "A") with no reported value, the BIIB sales were primarily coded as "F" (dispositions under Rule 16b-3), indicating planned sales rather than open-market transactions. The absence of any buying activity suggests a consistent divestment pattern, particularly in Biogen, where Robin has executed multiple sales annually. The most recent activity includes a February 13, 2026, award in BIIB and a March 9, 2026, award in ARMP, though neither involved monetary transactions. The data reflects a clear directional trend toward reducing equity exposure in these holdings over time.
AI-assisted summary